Ratio de margen de beneficio neto
desde 2005
Cálculo
Gilead Sciences Inc., ratio de margen de beneficio neto, tendencias a largo plazo, cálculo
| Ratio de margen de beneficio neto | = | 100 | × | Utilidad (pérdida) neta atribuible a Gilead1 | ÷ | Venta de productos1 | |
|---|---|---|---|---|---|---|---|
| 31 dic. 2020 | 0.51% | = | 100 | × | 123 | ÷ | 24,355 |
| 31 dic. 2019 | 24.35% | = | 100 | × | 5,386 | ÷ | 22,119 |
| 31 dic. 2018 | 25.16% | = | 100 | × | 5,455 | ÷ | 21,677 |
| 31 dic. 2017 | 18.03% | = | 100 | × | 4,628 | ÷ | 25,662 |
| 31 dic. 2016 | 45.07% | = | 100 | × | 13,501 | ÷ | 29,953 |
| 31 dic. 2015 | 56.32% | = | 100 | × | 18,108 | ÷ | 32,151 |
| 31 dic. 2014 | 49.44% | = | 100 | × | 12,101 | ÷ | 24,474 |
| 31 dic. 2013 | 28.46% | = | 100 | × | 3,075 | ÷ | 10,804 |
| 31 dic. 2012 | 27.57% | = | 100 | × | 2,592 | ÷ | 9,398 |
| 31 dic. 2011 | 34.60% | = | 100 | × | 2,804 | ÷ | 8,102 |
| 31 dic. 2010 | 39.26% | = | 100 | × | 2,901 | ÷ | 7,390 |
| 31 dic. 2009 | 40.74% | = | 100 | × | 2,636 | ÷ | 6,469 |
| 31 dic. 2008 | 39.55% | = | 100 | × | 2,011 | ÷ | 5,085 |
| 31 dic. 2007 | 43.27% | = | 100 | × | 1,615 | ÷ | 3,733 |
| 31 dic. 2006 | -45.98% | = | 100 | × | (1,190) | ÷ | 2,588 |
| 31 dic. 2005 | 44.99% | = | 100 | × | 814 | ÷ | 1,809 |
Fuente: Gilead Sciences Inc. (NASDAQ:GILD) | Net profit margin since 2005 (www.stock-analysis-on.net)
1 US $ en millones
Comparación con la competencia
Gilead Sciences Inc., ratio de margen de beneficio neto, tendencias a largo plazo, comparación con la competencia
| Gilead Sciences Inc. | AbbVie Inc. | Amgen Inc. | Eli Lilly & Co. | Illumina Inc. | Johnson & Johnson | Merck & Co. Inc. | Moderna Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Zoetis Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 dic. 2020 | 0.51% | 10.08% | 29.97% | 25.24% | 20.25% | 17.82% | 14.72% | -92.99% | 22.95% | 41.35% | 19.79% | 24.54% |
| 31 dic. 2019 | 24.35% | 23.69% | 35.32% | 37.27% | 28.28% | 18.42% | 21.01% | -853.73% | 31.45% | 26.91% | 14.47% | 23.96% |
| 31 dic. 2018 | 25.16% | 17.36% | 37.25% | 13.16% | 24.78% | 18.75% | 14.71% | -284.84% | 20.79% | 36.42% | 12.06% | 24.52% |
| 31 dic. 2017 | 18.03% | 18.82% | 9.08% | -0.89% | 26.38% | 1.70% | 5.97% | — | 40.55% | 20.41% | 10.64% | 16.28% |
| 31 dic. 2016 | 45.07% | 23.22% | 35.27% | 12.90% | 19.29% | 23.01% | 9.85% | — | 13.66% | 18.42% | 11.06% | 16.80% |
| 31 dic. 2015 | 56.32% | 22.50% | 33.13% | 12.07% | 20.79% | 21.99% | 11.25% | — | 14.25% | 15.50% | 11.64% | 7.11% |
| 31 dic. 2014 | 49.44% | 8.89% | 26.69% | 12.19% | 18.98% | 21.96% | 28.22% | — | 18.42% | 12.34% | 11.22% | 12.18% |
| 31 dic. 2013 | 28.46% | 21.97% | 27.93% | 20.27% | 8.82% | 19.40% | 10.00% | — | 42.65% | 20.16% | 9.73% | 11.05% |
| 31 dic. 2012 | 27.57% | 28.70% | 26.11% | 18.09% | 13.17% | 16.14% | 13.05% | — | 24.70% | 54.43% | 9.42% | 10.06% |
| 31 dic. 2011 | 34.60% | — | 24.08% | 17.90% | 8.21% | 14.87% | 13.05% | — | 14.84% | -49.74% | 11.34% | — |
| 31 dic. 2010 | 39.26% | — | 31.56% | 21.97% | 13.83% | 21.65% | 1.87% | — | 12.18% | -22.76% | 9.60% | — |
| 31 dic. 2009 | 40.74% | — | 32.09% | 19.82% | 10.85% | 19.82% | 47.04% | — | 17.27% | -17.88% | 8.41% | — |
| 31 dic. 2008 | 39.55% | — | 28.57% | -10.17% | 8.81% | 20.31% | 32.74% | — | 16.78% | -34.69% | 9.47% | — |
| 31 dic. 2007 | 43.27% | — | 22.12% | 15.85% | -75.89% | 17.31% | 13.54% | — | 16.82% | -84.46% | 7.81% | — |
| 31 dic. 2006 | -45.98% | — | 21.29% | 16.97% | 21.65% | 20.73% | 19.59% | — | 39.98% | -161.30% | 4.46% | — |
| 31 dic. 2005 | 44.99% | — | 30.56% | 13.52% | -28.40% | 20.61% | 21.04% | — | 15.76% | -144.19% | 8.48% | — |
Fuente: Gilead Sciences Inc. (NASDAQ:GILD) | Net profit margin since 2005 (www.stock-analysis-on.net)
Comparación con el sector industrial: Productos farmacéuticos, biotecnología y ciencias de la vida
Gilead Sciences Inc., ratio de margen de beneficio neto, tendencias a largo plazo, comparación con el sector industrial: productos farmacéuticos, biotecnología y ciencias de la vida
| Gilead Sciences Inc. | Productos farmacéuticos, biotecnología y ciencias de la vida | |
|---|---|---|
| 31 dic. 2020 | 0.51% | 17.80% |
| 31 dic. 2019 | 24.35% | 24.23% |
| 31 dic. 2018 | 25.16% | 19.63% |
| 31 dic. 2017 | 18.03% | 13.79% |
| 31 dic. 2016 | 45.07% | 21.04% |
| 31 dic. 2015 | 56.32% | 22.25% |
| 31 dic. 2014 | 49.44% | 22.46% |
| 31 dic. 2013 | 28.46% | 22.99% |
| 31 dic. 2012 | 27.57% | 19.40% |
| 31 dic. 2011 | 34.60% | 15.73% |
| 31 dic. 2010 | 39.26% | 15.52% |
| 31 dic. 2009 | 40.74% | 23.93% |
| 31 dic. 2008 | 39.55% | 18.13% |
| 31 dic. 2007 | 43.27% | 16.67% |
| 31 dic. 2006 | -45.98% | 24.52% |
| 31 dic. 2005 | 44.99% | 19.15% |
Fuente: Gilead Sciences Inc. (NASDAQ:GILD) | Net profit margin since 2005 (www.stock-analysis-on.net)
Comparación con la industria: Cuidado de la salud
Gilead Sciences Inc., ratio de margen de beneficio neto, tendencias a largo plazo, comparación con la industria: cuidado de la salud
| Gilead Sciences Inc. | Cuidado de la salud | |
|---|---|---|
| 31 dic. 2020 | 0.51% | 8.30% |
| 31 dic. 2019 | 24.35% | 11.39% |
| 31 dic. 2018 | 25.16% | 9.88% |
| 31 dic. 2017 | 18.03% | 8.06% |
| 31 dic. 2016 | 45.07% | 10.64% |
| 31 dic. 2015 | 56.32% | 11.54% |
| 31 dic. 2014 | 49.44% | 11.93% |
| 31 dic. 2013 | 28.46% | 12.51% |
| 31 dic. 2012 | 27.57% | 11.65% |
| 31 dic. 2011 | 34.60% | 10.56% |
| 31 dic. 2010 | 39.26% | 10.81% |
| 31 dic. 2009 | 40.74% | 15.25% |
| 31 dic. 2008 | 39.55% | 11.57% |
| 31 dic. 2007 | 43.27% | 11.15% |
| 31 dic. 2006 | -45.98% | 13.99% |
| 31 dic. 2005 | 44.99% | 13.43% |
Fuente: Gilead Sciences Inc. (NASDAQ:GILD) | Net profit margin since 2005 (www.stock-analysis-on.net)